All next-generation sequencing (NGS) procedures include assays performed at the laboratory bench ("wet bench") and data analyses conducted using bioinformatics pipelines ("dry bench"). Both elements are essential to produce accurate and reliable results, which are particularly critical for clinical laboratories. Targeted NGS technologies have increasingly found favor in oncology applications to help advance precision medicine objectives, yet the methods often involve disconnected and variable wet and dry bench workflows and uncoordinated reagent sets. In this report, we describe a method for sequencing challenging cancer specimens with a 21-gene panel as an example of a comprehensive targeted NGS system. The system integrates functional DNA quantification and qualification, single-tube multiplexed PCR enrichment, and library purification and normalization using analytically-verified, single-source reagents with a standalone bioinformatics suite. As a result, accurate variant calls from low-quality and low-quantity formalin-fixed, paraffin-embedded (FFPE) and fine-needle aspiration (FNA) tumor biopsies can be achieved. The method can routinely assess cancer-associated variants from an input of 400 amplifiable DNA copies, and is modular in design to accommodate new gene content. Two different types of analytically-defined controls provide quality assurance and help safeguard call accuracy with clinically-relevant samples. A flexible "tag" PCR step embeds platform-specific adaptors and index codes to allow sample barcoding and compatibility with common benchtop NGS instruments. Importantly, the protocol is streamlined and can produce 24 sequence-ready libraries in a single day. Finally, the approach links wet and dry bench processes by incorporating pre-analytical sample quality control results directly into the variant calling algorithms to improve mutation detection accuracy and differentiate false-negative and indeterminate calls. This targeted NGS method uses advances in both wetware and software to achieve high-depth, multiplexed sequencing and sensitive analysis of heterogeneous cancer samples for diagnostic applications.
Introduction
Precision medicine relies on the individualization of diagnostic and therapeutic options for patients. The promise of tailored treatments is a direct consequence of an improved understanding of disease pathways that can inform the linkage of molecular diagnostics and targeted therapeutics. For example, the use of molecularly-targeted therapies increased from 11% to 46% from 2003 to 2013 1 , and anti-cancer drugs such as vemurafenib and crizotinib are FDA-cleared with companion diagnostic tests. With its ability to accurately recover low-abundance sequence targets across highly multiplexed sample sets, next-generation sequencing (NGS) has emerged as a method of choice for evaluating genetic aberrations associated with cancer and identifying molecular targets for precision medicine.
DNA Functional Quantification and Quality Control (QC)
1. Thaw reagents: 2x Master Mix, Primer Probe Mix, Inhibition Primer Probe Mix, 6-carboxy-X-rhodamine (ROX), Diluent, and the four human genomic DNA calibration curve standards (DNA Standard (50 ng/µl), DNA Standard (10 ng/µl), DNA Standard (2 ng/µl), and DNA Standard (0.4 ng/µl)) ( Table 1) . Vortex all reagents for 10 sec and centrifuge at maximum speed for 10 sec to collect contents. Keep the 2x master mix on ice. 2. Prepare a sufficient amount of master mix for the total number of samples to be tested and include 10% more volume to avoid shortages due to pipetting. Prepare the master mix in a microcentrifuge tube using the following volumes per sample: 5 µl 2x Master Mix, 0.5 µl Primer Probe Mix, 0.5 µl Inhibition Primer Probe Mix, 0.05 µl ROX and 2.95 µl Diluent. Vortex for 10 sec and centrifuge at maximum speed for 10 sec to collect contents. 3. Add 9 µl master mix into wells of a 96-well plate. 4. Add 1 µl of the DNA Standards in duplicate to generate a calibration curve. Mix by pipetting up-and-down 5 times. 5. Ensure the nucleic acid sample is well mixed before use. Add 1 µl sample to the master mix and mix by pipetting up-and-down 5 times. 6. Seal the plate, vortex for 10 sec and centrifuge at maximum speed for 10 sec to collect contents. 7. Place the plate into the PCR System. Assign both FAM (functional quantification) and VIC (functional inhibition) detectors for each sample according to the manufacturer's instructions. Perform PCR cycles of 10 min at 95 °C, and 40 cycles (15 sec at 95 °C, 1 min at 60 °C). 8. Analyze the qPCR data by generating a linear regression plot for each of the duplicate DNA standards using software protocols. 9. Plot the Log 10 of the copy number for each DNA standard on the x-axis and the corresponding FAM C q value on the y-axis. 10. Confirm that the results from the nucleic acid sample fall within the dynamic range of the DNA Standards calibration curve, and then calculate the concentration of the unknown DNA in "functional" or amplifiable copy number per µl from its corresponding position on the reference standard curve. Figure 1 shows examples of calibration curves that passed and failed. 11. Determine if amplification occurred in each reaction by checking for the presence of the non-human target amplicon in the VIC channel.
Note: As a positive control, the Inhibition Primer Probe Mix contains primers specific for a non-human exogenous target and the corresponding template. The Inhibition Primer Probe Mix is a component of the master mix which is added to each reaction, including the notemplate control (NTC). In absence of an inhibitor, the PCR product for the non-human target should always be detected in the VIC channel. An "undetected" C q for a sample in the VIC channel indicates the presence of PCR inhibitors that may benefit from subsequent clean-up of the sample prior to further processing.
Library Preparation: Gene-specific (GS) PCR
1. Prepare a sufficient amount of master mix for the total number of samples to be tested and include 10% more volume to avoid shortages due to pipetting. Prepare the GS PCR master mix in a microcentrifuge tube using the following volumes per sample: 5 µl 2x Amplification Master Mix ( Note: After completion of step 2.4, the plate will be referred to as the GS PCR plate.
Library Preparation: Tag PCR
1. Thaw reagents: 2x Index Master Mix ( Table 1) and Index Codes ( Table 1) . Vortex for 10 sec and centrifuge at maximum speed for 10 sec to collect contents. Note: Index Codes are premixed to provide a unique set of pairwise indices (barcodes) for each sample. 2. In a 96-well plate, add 7.5 µl of the 2x Index Master Mix and 5.5 µl of an Index Code to a specified well and mix by pipetting up-and-down 5 times. 3 . Carefully open the GS PCR plate, and add 2 µL GS PCR product to the new plate with the master mix. Mix by pipetting up-and-down 5 times.
For each sample, record the Sample ID and the corresponding pairwise Index Codes. Seal the plate, vortex for 10 sec and centrifuge at maximum speed for 10 sec to collect contents. 
Data Analysis
Note: The NGS instrument software converts cluster images to base calls and quality scores, and demultiplexes pairwise indices to generate individual gzip-compressed FASTQ (*.fastq.gz) files for each sample. Prior to analyzing the demultiplexed files, the reader must download and install the associated bioinformatics software ( Table 1 ). The software can be installed on a consumer-grade Windows PC and does not require specialized computing hardware or an internet connection to perform the data analysis.
1. Double-click the software desktop icon. 2. Login to the system using the username and password provided in the software manual. 3. Open the project dashboard, and click "New Project". 1. Name the project and provide an optional project description. Select the targeted NGS panel type and NGS instrument type. Click "Save and continue". 2. Upload the compressed FASTQ files for the forward and reverse reads. Do not upload the "unassigned" FASTQs, which contain reads that failed to demultiplex. Click "Save and continue". 3. Input the number of functional input copies used to prepare each library as determined by the DNA functional quantification assay (see
Step 1 above). Manually add values or copy and paste values from a spreadsheet into the annotation table. Click "Save and continue." 4. Review the annotated libraries uploaded for analysis and click "Submit analysis" to initiate the analysis. 
Representative Results
A total of 90 samples (74 unique) representing positive and negative controls, previously characterized cell lines, and residual clinical FFPE tumor biopsies were assessed for amplifiable DNA, input into multiplex PCR enrichment, tagged with sequence adapters, barcoded, and analyzed in a single benchtop NGS instrument run (Figure 2 ) that produced 19.1 M reads passing filter. Equimolar sample pooling resulted in high depth sequencing (3,692x reads) and uniform coverage (97.8% of amplicons covered within 5-fold of the median read depth). Outliers comprised no-template controls, one cell-line DNA with a large copy number amplification, and one FFPE DNA that was flagged for PCR inhibition by the pre-analytical QC assay (Figure 3) . Coverage uniformity across the 46 amplicons was maintained using three different operators ( Figure 4A) , and for different low-quality FFPE DNA samples ( Figure 4B ). An FFPE tumor DNA control, formulated from a mixture of residual clinical specimens to achieve 5% BRAF V600E (quantified by droplet digital PCR), was reported to have the target BRAF mutation at abundances of 3.9, 5.3, and 6.5% by three operators using an input of 400 amplifiable copies (and thus only 20 mutant copies) ( Figure 4B and "FFPE3" of inset table). Further, a mixture of 12 synthetic DNA templates, each representing a known "driver" base-substitution mutation, revealed the expected mutations at the intended range of 9 -17% mean allele frequency ( Table 2 ). Dilution of cell-line and FFPE DNA samples with copy number amplifications demonstrated dose-dependence for variants in EGFR and KRAS, respectively ( Figure 5) . Importantly, FFPE DNA input could be reduced to as few as 50 amplifiable copies or 1.2 ng of bulk DNA while preserving the detection of known mutations without false-positive calls (Figure 6 ). DNA inputs were accommodated over a 100-fold range up to at least 50,000 amplifiable copies ( Table 3) . In this and related experiments, variant calls in 22 FFPE and 20 FNA specimens were reported in agreement with independent methods with shared mutation coverage ( Table 4) . Table 3 : Coverage and Variant Calling are Preserved Over a >100-fold Range of DNA Input. Amplifiable DNA from a BCPAP cell line was input into multiplex PCR enrichment at 400 to 50,000 copies and sequenced. Read depth, coverage uniformity, mutation detection, and mutation accuracy were preserved across the input range. A set of 22 FFPE tumor DNA with mutation status previously determined by orthogonal targeted NGS assays was input at 400 to 2,928 amplifiable copies into the PCR enrichment step and sequenced using the 21-gene Pan Cancer panel. In addition, a cohort of 20 FNA DNA samples previously characterized using a liquid bead array mutation assay 8 was PCR amplified using 156 to 36,080 input amplifiable copies and sequenced. All overlapping calls between the Pan Cancer NGS panel and the reference methods were in agreement. Please click here to view a larger version of this figure.
Discussion
NGS technologies have redefined expectations for interrogating the molecular profiles of tumor biopsies in clinical settings 9 . A number of targeted NGS panels have been developed as research technologies, laboratory developed tests, and commercially available products and custom panels for assessing multiple types of clinical specimens 3, 5, [10] [11] [12] [13] [14] [15] . Reports from multiple studies have demonstrated the value of NGS as a sensitive and specific clinical tool for the detection of genomic alterations 3, [10] [11] [12] 14 . Yet studies have also demonstrated the risk of artifacts which can cause false-positive results from challenging cancer biopsies such as FFPE specimens [2] [3] [4] [5] 12, 14 . Additionally, recent publications have highlighted high failure rates for NGS using oncology specimens 16 and false-positive calls with commercial targeted NGS panels that are aggravated by the use of low-input DNA 12 . As a result, some laboratories have either modified or added additional checks and balances to commercially available targeted NGS technologies to improve performance, often to ensure accuracy or confirm the findings from the bioinformatic analyses 5, 10, 11 .
The 21-gene panel (Figure 2 ) was developed as targeted content for a comprehensive NGS system to interrogate evidence-based, actionable mutations in challenging specimen types such as FFPE and FNA tumor biopsies. The workflow has a number of benefits: 1) consistency by providing uniform amplicon coverage (Figures 3 and 4, Table 3) ; 2) ease-of-use by providing pre-formulated, optimized reagent sets, and simplifying the bioinformatics requirements; 3) efficiency by streamlining the workflow and reducing the number of pipetting steps as compared to other commercial NGS methods; and 4) accuracy by incorporating a DNA QC assay for assessing the amplifiable DNA copy number to ensure acceptable template diversity and avoid stochastic fluctuations in variant detection 4 . The integration of the pre-analytical QC data with the bioinformatics analysis allows for low inputs of FFPE DNA. This was achieved by training a decision-tree algorithm using different functional copies of DNA input across 400 FFPE samples with independent measures of truth, and incorporating this algorithm into the bioinformatic software. As a result, the recommended input of 400 amplifiable copies, typically equivalent to ~5-20 ng of FFPE DNA, compares favorably to other methods [10] [11] [12] , including hybridization-based enrichment where ~250 ng of FFPE DNA is recommended 17, 18 . Although the technique is described for use on a MiSeq platform, it can be modified by using Tag PCR primers with instrument-specific adaptors to enable sequence analysis on other NGS platforms.
of a false-negative call from samples with low-abundance mutations (Figure 6) . Additionally, care must be taken during library purification to prevent over-drying of the magnetic beads during the washing or elution steps. Furthermore, successful library quantification is highly dependent on the accurate dilution of library DNA. For the best outcome, the difference of the qPCR results for the sample library (Cq FAM) compared to the LQ Standard (Cq VIC) should be ≤3.3 Cq. If the difference is greater than 3.3 Cq, re-dilution and testing of the sample is recommended. Although an excellent correlation has been observed between this competitive qPCR method and commercial kits that offer absolute quantification using a standard curve, an offset of the library input into the clonal amplification step relative to other methods may be necessary to achieve optimal seeding density.
Some cancer specimens are particularly challenging to sequence because of inhibitors that persist after DNA isolation. To identify these samples prior to library preparation, the qPCR QC assay also detects amplification inhibition by including an exogenous template that serves as both an internal control and a sentinel for functional inhibition. An example is presented in Figure 3 in which a melanoma DNA sample failed to pass the QC inhibition metric prior to sequencing and then failed to generate a library that could be sequenced. The failure was likely a consequence of melanin contamination, a known PCR inhibitor, carried over from the FFPE DNA isolation step. Samples that are identified by the QC assay to be at risk for amplification failure may be salvaged through an extra clean-up step to remove potential inhibitors.
The targeted 21-gene panel focuses on evidence-based gene hotspots and provides a complete system with optimized reagents and controls for DNA QC, NGS and bioinformatics software that is informed by pre-analytical "functional" DNA quantification results. The method accurately detects base-substitution mutations and indels from low-input DNA, and provides an example of an NGS system with the option to expand panel content, to detect additional variants such as CNVs and be adapted for targeted RNA sequencing.
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